Clinical Trial Update: A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase II open-label trial evaluating RC48-ADC in HER2-overexpressing locally advanced or metastatic urothelial cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Urothelial Carcinoma | Phase 2 | Status: COMPLETED